S*BIO Announces US$5 Million Investment by Mitsui Ventures
S*BIO Pte Ltd announced a US$5 million investment by Mitsui Ventures that will support the continued development of S*BIO’s clinical programs.
“Mitsui Ventures’ financing commitment reflects the international investment community’s strong interest in our track record in advancing multiple assets through clinical development and the quality of our various preclinical and clinical programs,” said Dr. Jan-Anders Karlsson, CEO of S*BIO. “The involvement of Mitsui Ventures broadens our investor base and also enhances the company’s profile and standing in Japan and Asia.”
This investment follows the recent patient enrolment completion of S*BIO’s Phase 2 clinical trials with its orally-active JAK2 inhibitor, SB1518. S*BIO’s other lead compound SB939, a novel HDAC inhibitor is scheduled to enter Phase 2 Studies in Q3 2010.
Most read news
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents

Less chewing the cud, more greening the fuel

First 3-D structure of DHHC enzymes reported
Millipore Forms Collaboration with Agilent Technologies to Expand Capabilities in Epigenetics Research Market

Obesity treatment could offer dramatic weight loss without surgery or nausea

Dr. Roland Durner becomes new CEO of Bioengineering AG

Sustainable scents from the mountain of the gods - ETH Zurich chemist Michailidou could see herself founding her own start-up: “That would be a dream come true”
Telormedix’ TMX-101 Commences Clinical Trial for Bladder Cancer
